Suppression of cytomegalovirus retinitis in persons with AIDS with high-dose intravenous acyclovir

Beverly E. Sha; Constance A. Benson; Thomas A. Deutsch; Pamela A. Urbanski; John P. Phair; Harold A. Kessler

doi:10.1093/infdis/164.4.777

Suppression of cytomegalovirus retinitis in persons with AIDS with high-dose intravenous acyclovir

Beverly E. Sha, Constance A. Benson, Thomas A. Deutsch, Pamela A. Urbanski, John P. Phair, Harold A. Kessler^*

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

To evaluate the efficacy and safety of high-dose intravenous acyclovir combined with oral zidovudine as suppressive therapy for cytomegalovirus retinitis in patients with AIDS, a single-arm, outpatient, open-label, phase II pilot study was performed. Between July 1989 and July 1990, 12 men with AIDS, cytomegalovirus retinitis, and salvageable vision received intravenous acyclovir, 10 mg/kg of body weight every 8 h, and oral zidovudine after successful induction therapy with intravenous ganciclovir, 5 mg/kg every 12 h for 14 days. Patients were evaluated weekly. Ten of 12 patients were followed to the time of retinitis progression; two were withdrawn from the study because of concomitant life-threatening infection. The median duration of acyclovir and zidovudine therapy before retinitis progression occurred was 32 days. None of the eight uninvolved eyes in the 10 evaluatable patients developed cytomegalovirus retinitis during study participation. These data suggest that high-dose intravenous acyclovir with zidovudine provides some benefit in suppressing cytomegalovirus retinitis.

Original language	English (US)
Pages (from-to)	777-780
Number of pages	4
Journal	Journal of Infectious Diseases
Volume	164
Issue number	4
DOIs	https://doi.org/10.1093/infdis/164.4.777
State	Published - Oct 1991

Funding

Received 10 December 1990; revised 16 April 1991. Presented in part: VI International Conference on AIDS. San Francisco. June 1990 (abstract Th.B.441). The study protocol was approved by the institutional Human Investigation Committee in accordance with guidelines of the US Department of Health and Human Services; written informed consent was obtained from all participants. Financial support: National Institute of Allergy and Infectious Diseases. Division of AIDS. Reprints or correspondence: Dr. Harold A. Kessler. Section of Infectious Diseases. Rush-Presbyterian-St. Luke's Medical Center. 600 S. Paulina. Suite 143. Chicago. IL 60612.

ASJC Scopus subject areas

Infectious Diseases
Immunology and Allergy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/infdis/164.4.777

Cite this

@article{3643f8ebcac042bbb66acddae017fed1,

title = "Suppression of cytomegalovirus retinitis in persons with AIDS with high-dose intravenous acyclovir",

abstract = "To evaluate the efficacy and safety of high-dose intravenous acyclovir combined with oral zidovudine as suppressive therapy for cytomegalovirus retinitis in patients with AIDS, a single-arm, outpatient, open-label, phase II pilot study was performed. Between July 1989 and July 1990, 12 men with AIDS, cytomegalovirus retinitis, and salvageable vision received intravenous acyclovir, 10 mg/kg of body weight every 8 h, and oral zidovudine after successful induction therapy with intravenous ganciclovir, 5 mg/kg every 12 h for 14 days. Patients were evaluated weekly. Ten of 12 patients were followed to the time of retinitis progression; two were withdrawn from the study because of concomitant life-threatening infection. The median duration of acyclovir and zidovudine therapy before retinitis progression occurred was 32 days. None of the eight uninvolved eyes in the 10 evaluatable patients developed cytomegalovirus retinitis during study participation. These data suggest that high-dose intravenous acyclovir with zidovudine provides some benefit in suppressing cytomegalovirus retinitis.",

author = "Sha, {Beverly E.} and Benson, {Constance A.} and Deutsch, {Thomas A.} and Urbanski, {Pamela A.} and Phair, {John P.} and Kessler, {Harold A.}",

note = "Funding Information: Received 10 December 1990; revised 16 April 1991. Presented in part: VI International Conference on AIDS. San Francisco. June 1990 (abstract Th.B.441). The study protocol was approved by the institutional Human Investigation Committee in accordance with guidelines of the US Department of Health and Human Services; written informed consent was obtained from all participants. Financial support: National Institute of Allergy and Infectious Diseases. Division of AIDS. Reprints or correspondence: Dr. Harold A. Kessler. Section of Infectious Diseases. Rush-Presbyterian-St. Luke's Medical Center. 600 S. Paulina. Suite 143. Chicago. IL 60612.",

year = "1991",

month = oct,

doi = "10.1093/infdis/164.4.777",

language = "English (US)",

volume = "164",

pages = "777--780",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Suppression of cytomegalovirus retinitis in persons with AIDS with high-dose intravenous acyclovir

AU - Sha, Beverly E.

AU - Benson, Constance A.

AU - Deutsch, Thomas A.

AU - Urbanski, Pamela A.

AU - Phair, John P.

AU - Kessler, Harold A.

N1 - Funding Information: Received 10 December 1990; revised 16 April 1991. Presented in part: VI International Conference on AIDS. San Francisco. June 1990 (abstract Th.B.441). The study protocol was approved by the institutional Human Investigation Committee in accordance with guidelines of the US Department of Health and Human Services; written informed consent was obtained from all participants. Financial support: National Institute of Allergy and Infectious Diseases. Division of AIDS. Reprints or correspondence: Dr. Harold A. Kessler. Section of Infectious Diseases. Rush-Presbyterian-St. Luke's Medical Center. 600 S. Paulina. Suite 143. Chicago. IL 60612.

PY - 1991/10

Y1 - 1991/10

N2 - To evaluate the efficacy and safety of high-dose intravenous acyclovir combined with oral zidovudine as suppressive therapy for cytomegalovirus retinitis in patients with AIDS, a single-arm, outpatient, open-label, phase II pilot study was performed. Between July 1989 and July 1990, 12 men with AIDS, cytomegalovirus retinitis, and salvageable vision received intravenous acyclovir, 10 mg/kg of body weight every 8 h, and oral zidovudine after successful induction therapy with intravenous ganciclovir, 5 mg/kg every 12 h for 14 days. Patients were evaluated weekly. Ten of 12 patients were followed to the time of retinitis progression; two were withdrawn from the study because of concomitant life-threatening infection. The median duration of acyclovir and zidovudine therapy before retinitis progression occurred was 32 days. None of the eight uninvolved eyes in the 10 evaluatable patients developed cytomegalovirus retinitis during study participation. These data suggest that high-dose intravenous acyclovir with zidovudine provides some benefit in suppressing cytomegalovirus retinitis.

AB - To evaluate the efficacy and safety of high-dose intravenous acyclovir combined with oral zidovudine as suppressive therapy for cytomegalovirus retinitis in patients with AIDS, a single-arm, outpatient, open-label, phase II pilot study was performed. Between July 1989 and July 1990, 12 men with AIDS, cytomegalovirus retinitis, and salvageable vision received intravenous acyclovir, 10 mg/kg of body weight every 8 h, and oral zidovudine after successful induction therapy with intravenous ganciclovir, 5 mg/kg every 12 h for 14 days. Patients were evaluated weekly. Ten of 12 patients were followed to the time of retinitis progression; two were withdrawn from the study because of concomitant life-threatening infection. The median duration of acyclovir and zidovudine therapy before retinitis progression occurred was 32 days. None of the eight uninvolved eyes in the 10 evaluatable patients developed cytomegalovirus retinitis during study participation. These data suggest that high-dose intravenous acyclovir with zidovudine provides some benefit in suppressing cytomegalovirus retinitis.

UR - http://www.scopus.com/inward/record.url?scp=0026009379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026009379&partnerID=8YFLogxK

U2 - 10.1093/infdis/164.4.777

DO - 10.1093/infdis/164.4.777

M3 - Article

C2 - 1654361

AN - SCOPUS:0026009379

SN - 0022-1899

VL - 164

SP - 777

EP - 780

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 4

ER -

Suppression of cytomegalovirus retinitis in persons with AIDS with high-dose intravenous acyclovir

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this